Microbix Biosystems Inc. (TSX:MBX)
Canada · Delayed Price · Currency is CAD 0.3200
0.00 (0.00%)
Aug 28, 2026, 9:33 AM EST
Microbix Biosystems Income Statement
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 15.4 | 18.59 | 25.39 | 16.51 | 19.08 | 18.59 | |
Revenue Growth | -27.13% | -26.81% | 53.77% | -13.43% | 2.60% | 76.66% |
Cost of Revenue | 8.33 | 8.73 | 10 | 9.03 | 7.95 | 7.55 |
Gross Profit | 7.07 | 9.85 | 15.39 | 7.48 | 11.12 | 11.04 |
Selling, General & Admin | 8.98 | 9.1 | 9.37 | 8.17 | 6.72 | 5.17 |
Research & Development | 2.36 | 2.33 | 2.13 | 2.05 | 1.8 | 1.03 |
Operating Expenses | 11.34 | 11.43 | 11.49 | 10.22 | 8.51 | 6.21 |
Operating Income | -4.28 | -1.58 | 3.9 | -2.74 | 2.61 | 4.84 |
Interest Expense | -1.01 | -0.95 | -0.92 | -0.84 | -0.83 | -1.6 |
Interest & Investment Income | 0.26 | 0.35 | 0.69 | 0.46 | 0.08 | 0 |
Currency Exchange Gain (Loss) | 0.09 | -0.13 | 0.01 | - | - | - |
Other Non Operating Income (Expenses) | -0 | - | -0 | - | - | - |
EBT Excluding Unusual Items | -4.94 | -2.3 | 3.67 | -3.12 | 1.87 | 3.23 |
Asset Writedown | - | - | - | 3.08 | - | - |
Pretax Income | -4.94 | -2.3 | 3.67 | -0.04 | 1.87 | 3.23 |
Income Tax Expense | -0.06 | -0.06 | 0.15 | - | 0.08 | - |
Net Income | -4.88 | -2.25 | 3.52 | -0.04 | 1.79 | 3.23 |
Net Income to Common | -4.88 | -2.25 | 3.52 | -0.04 | 1.79 | 3.23 |
Net Income Growth | - | - | - | - | -44.68% | - |
Shares Outstanding (Basic) | 138 | 139 | 138 | 138 | 135 | 115 |
Shares Outstanding (Diluted) | 138 | 139 | 138 | 138 | 142 | 142 |
Shares Change | -1.62% | 0.48% | 0.42% | -2.67% | 0.00% | 35.14% |
EPS (Basic) | -0.04 | -0.02 | 0.03 | -0.00 | 0.01 | 0.03 |
EPS (Diluted) | -0.04 | -0.02 | 0.03 | -0.00 | 0.01 | 0.03 |
EPS Growth | - | - | - | - | -49.98% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Free Cash Flow | -3.89 | -0.88 | 2.71 | -2.11 | 1.44 | 0.86 |
Free Cash Flow Per Share | -0.03 | -0.01 | 0.02 | -0.01 | 0.01 | 0.01 |
Gross Margin | 45.90% | 53.02% | 60.61% | 45.30% | 58.32% | 59.40% |
Operating Margin | -27.77% | -8.48% | 15.35% | -16.57% | 13.68% | 26.01% |
Profit Margin | -31.72% | -12.08% | 13.86% | -0.24% | 9.38% | 17.39% |
Free Cash Flow Margin | -25.25% | -4.72% | 10.68% | -12.78% | 7.55% | 4.65% |
EBITDA | -3.06 | -0.14 | 5.19 | -1.9 | 3.33 | 5.39 |
EBITDA Margin | -19.84% | -0.75% | 20.46% | -11.48% | 17.45% | 28.97% |
D&A For EBITDA | 1.22 | 1.44 | 1.3 | 0.84 | 0.72 | 0.55 |
EBIT | -4.28 | -1.58 | 3.9 | -2.74 | 2.61 | 4.84 |
EBIT Margin | -27.77% | -8.48% | 15.35% | -16.57% | 13.68% | 26.01% |
Effective Tax Rate | - | - | 4.10% | - | 4.14% | - |
Revenue as Reported | 15.4 | 18.59 | 25.39 | 16.51 | 19.08 | 18.59 |